Following the FDA’s approval of DUVYZAT™ (givinostat) on March 21, 2024, ITF Therapeutics, LLC, the company responsible for producing and marketing DUVYZAT™ in the United States, today shared an update on the drug and related resources.

ITF Therapeutics has launched the DUVYZAT™ website, which provides Indication and Important Safety Information, a comprehensive list of FAQs, full Prescribing Information, a Patient Medication Guide, as well as an opportunity for individuals to sign up for updates on DUVYZAT™.

ITF Therapeutics has indicated that they expect DUVYZAT™ to be available in Q3 of 2024 and that the company will be hosting informational webinars for members of the Duchenne community in the near future.

PPMD RESOURCES

PPMD has requested to host a webinar with ITF Therapeutics on Wednesday, March 27th at 1:00 PM ET to provide the community with an opportunity to meet members of the ITF Therapeutics team to learn more about their organization and next steps to support the availability of DUVYZAT™. Register now and submit your questions in advance here.

Access PPMD’s resource of FAQs surrounding the approval of DUVYZAT™ and what this means, including questions on eligibility and access here.